The Kia Syros features a traditional boxy SUV design, with clear inspiration from the Kia EV9 and gets plenty of upmarket features Bookings for the Kia Syros already underway for a token amount of ...

SHREYASH YUVA FOUNDATION is a Private Limited Company, governed by the Companies Act as a company limited by shares. Classified as a Non-government company, it is registered under the Registrar of ...

Nagpur: Shivaji Gymnastics Club emerged victorious at the prestigious Khasdar Krida Mahotsav 2025, winning the Overall Artistic Girls Championship. The competition, held on January 23 and 24, 2025 ...

Amid the tough loss, vice-captain Shreyash Kadam emerged as the standout performer for the Falcons. His spirited innings of 31 runs off just 13 balls, featuring two boundaries and three towering sixes ...

Mumbai, with a strategic chase, claimed victory with six wickets remaining, according to an ISPL release. Vice-captain Shreyash Kadam emerged as the shining star amid the Falcons' struggles, scoring ...

In his international debut in Sharjah, Shreyash smashed three consecutive sixes out of the stadium against Pakistan's Zaheer Kalia, a fearsome bowler known for his 150-160 kmph pace, whom even top ...

Robin Singh sheds light on City vs Real UCL clash, says 'Madrid will cause damage in attacking sector' ...

Fluorescence in situ hybridization using fusion probes for the BCR and ABL is another widely used technique, particularly in the USA. It is more sensitive than traditional cytogenetic analyses and ...

1 Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, China 2 Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of ...

Vice-chancellor Dr Prashant Bokare, acting Pro-VC Rajendra Kakade, registrar Raju Hiwase, finance and accounts officer Harish Paliwal, dean of the faculty of science and technology Dr Prashant ...

In summary, mutation delectation rate was higher in patients who did not achieve MCyR by 12 months or CCyR by 18 months of imatinib therapy, patients who lost response (CHR, MCyR, CCyR and MMR ...